| |
Douglas M. Fambrough, Ph.D.
Venture Partner
Boston, MA
dfambrough@oxbio.com |
Dr. Fambrough is a Venture Partner with OBP and serves as CEO of OBP portfolio company Dicerna Pharmaceuticals, a second generation "RNA Interference" company which he co-founded. Dr. Fambrough joined OBP in 1999, most recently acting as a General Partner specializing in financing innovative life science technology companies. He currently represents OBP on the boards of Xencor, a protein engineering company that engineers antibody Fc regions to enhance drug potency, and Solstice Neurosciences, which markets the protein drug Myobloc for movement disorders. His past investments include Dicerna Pharmaceuticals; first generation RNA Interference pioneer Sirna Therapeutics, acquired by Merck for $1.1 billion; the ultra-high-throughput DNA sequencing equipment company Solexa, acquired by Illumina for $600 million; and Cambrios Technologies, which invented and now markets biologically-inspired electronic materials for touch screens, flat panel displays, and photovoltaics. Prior to Oxford, Dr. Fambrough was a genomic scientist at the Whitehead/MIT Center for Genome Research (now known as the Broad Institute). He graduated from Cornell University and obtained his Ph.D. in genetics from the University of California, Berkeley.
Back to OBP Team
|
|